Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas

Inclusion Criteria Patients must have the following: * Positive HIV antibody, positive HIV culture or antigen capture, or prior diagnosis of AIDS by the CDC criteria. * Diagnosis by pathological examination of large cell or immunoblastic lymphoma within measurable or evaluable disease. * Pneumocystis carinii pneumonia (PCP) prophylaxis during the course of the study. * Signed written informed consent. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks. * Stage IE Central Nervous System lymphomas. Patients with the following are excluded: * More than one previous treatment for lymphoma. * Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks. * Conditions that preclude obtaining an informed consent. * Not accessible for scheduled treatment visits or follow-up. * Stage IE Central Nervous System (CNS) lymphomas. Prior Medication: Excluded within 2 weeks of study entry: * Zidovudine. * Excluded: * Doxorubicin dosing = or \> 300 mg/m2. Prior Treatment: Excluded: * Received more than one previous treatment regimen for lymphoma. Required: * Prophylactic treatment for Pneumocystis carinii pneumonia (PCP) prophylaxis.